BB Biotech AG : Newsflow opérationnel et activité M&A comme catalyseurs au T4
>Un T3 challenging, performance à 9M toujours dans le vert - BB Biotech publie ce matin ses résultats au titre du T3 2020, le titre de la holding a perdu 4.3% en € et 3.4% en CHF sur le trimestre. La NAV du portefeuille a reculé quant à elle de 10.9 % en CHF, de 12.1% en € et de 8.3 % en $ sous-performant son indice de référence le NBI (Nasdaq Biotechnology Index) qui lui n’a reculé que de -0.8 % sur la période. Il en résulte une perte nette de -395 MCHF (vs -382 MCH...Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.